Sector Chart MediciNova, Inc.

Stocks

MNOV

US58468P2065

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:05:25 2026-10-28 EDT			5-day change	1st Jan Change
1.465 ^USD	+3.90%		+3.55%	+11.45%

10-12	MediciNova Phase 2 Trial in Fatty Liver Disease Drug Misses Primary Endpoints	MT
10-12	Medicinova, Inc. Provides Update on Mn-001 Phase 2 Clinical Trial Results and Mn-166 Combat-Als Trial	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes